仿制药品价格政策述评  

Review of generic drug price policy

作　　者：傅鸿鹏 朱雅萌 FU Hong-peng;ZHU Ya-meng

机构地区：[1]国家卫生健康委员会卫生发展研究中心,北京100032 [2]首都医科大学,北京100191

出　　处：《中国药物经济学》2018年第11期26-30,共5页China Journal of Pharmaceutical Economics

摘　　要：为进一步提高药品在中国的可及性,减轻医疗费用,中国政府正在逐步完善仿制药品价格政策。本文通过查阅整理相关文献,描述了仿制药品政策总体目标、管理体系以及各国相应的价格管制措施,在此基础之上提出对仿制药品价格政策进一步完善的相关思考和建议。In order to further improve the accessibility of drugs in China and reduce medical expenses, the Chinese government is gradually improving the generic drug price policy. This paper describes the objectives and systems of the generic drug policy and the management ideas of each country by consulting and collating relevant literature. On this basis, it puts forward relevant thoughts and suggestions on the further improvement of the generic drug price policy.

关 键 词：仿制药品 价格 卫生费用 

分 类 号：R951[医药卫生—药学]